GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Posaconazole delayed-release tablets (adult prophylaxis)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons

Noxafil delayed-release tablets

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Posaconazole delayed-release tablets (adult prophylaxis) - selected U.S. labeling

Product / population
Adults receiving fungal prophylaxis with whole oral 100 mg delayed-release posaconazole tablets. The selected generic label is prophylaxis-only; oral suspension, PowderMix and IV formulations are excluded.
Renal measure
eGFR mL/min/1.73 m2 for exposure-monitoring caution, not a reduced-dose algorithm.
Labeled basic dosing

For prophylaxis of invasive Aspergillus/Candida infections in severely immunocompromised adults: 300 mg orally twice on day 1, then 300 mg once daily from day 2. Duration follows recovery from neutropenia or immunosuppression. Swallow tablets whole.

Renal information and dialysis

The label keeps the same dosing in renal impairment. At eGFR below 20 mL/min/1.73 m2, monitor especially closely for breakthrough fungal infection because exposure is variable. Hemodialysis does not remove posaconazole.

Selected warnings and limits

Do not substitute liquid formulations. Review CYP3A4 interactions, tacrolimus/cyclosporine exposure, QT/electrolyte risks and liver tests.

Source revision: Label revision date not separately recorded; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f795eca-7a03-4c91-9a0e-c1235791b665

Scope: Selected dosing/renal sections read; concise local summary, not full prescribing information. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

Posaconazole delayed-release tablets (adult prophylaxis) - selected U.S. labeling

Adults receiving fungal prophylaxis with whole oral 100 mg delayed-release posaconazole tablets. The selected generic label is prophylaxis-only; oral suspension, PowderMix and IV formulations are excluded.

Renal method: eGFR mL/min/1.73 m2 for exposure-monitoring caution, not a reduced-dose algorithm.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

UCSF posaconazole - oral DR subset

Adults receiving fungal prophylaxis with whole oral 100 mg delayed-release posaconazole tablets. The selected generic label is prophylaxis-only; oral suspension, PowderMix and IV formulations are excluded.

Renal method: Qualitative renal/HD guidance; CVVHD assumption from source
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Official source

Posaconazole delayed-release tablets (adult prophylaxis) - selected U.S. labeling

Adults receiving fungal prophylaxis with whole oral 100 mg delayed-release posaconazole tablets. The selected generic label is prophylaxis-only; oral suspension, PowderMix and IV formulations are excluded.

Method: eGFR mL/min/1.73 m2 for exposure-monitoring caution, not a reduced-dose algorithm.

Renal information and dialysisRead this complete source summary
Professional source

UCSF posaconazole - oral DR subset

Adults receiving fungal prophylaxis with whole oral 100 mg delayed-release posaconazole tablets. The selected generic label is prophylaxis-only; oral suspension, PowderMix and IV formulations are excluded.

Method: Qualitative renal/HD guidance; CVVHD assumption from source

Source-specific renal protocolRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopePosaconazole delayed-release tablets (adult prophylaxis) - selected U.S. labelingUCSF posaconazole - oral DR subset
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f795eca-7a03-4c91-9a0e-c1235791b665

Product and population scope

Adults receiving fungal prophylaxis with whole oral 100 mg delayed-release posaconazole tablets. The selected generic label is prophylaxis-only; oral suspension, PowderMix and IV formulations are excluded.

RDM31-posaconazole-dr-scope · Source section: Editorial scope tied to selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Posaconazole delayed-release tablets (adult prophylaxis) - selected U.S. labeling

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · Adults receiving fungal prophylaxis with whole oral 100 mg delayed-release posaconazole tablets. The selected generic label is prophylaxis-only; oral suspension, PowderMix and IV formulations are excluded.

Renal method: eGFR mL/min/1.73 m2 for exposure-monitoring caution, not a reduced-dose algorithm.
Source date: Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved: 2026-09-05

Selected dosing/renal sections read; concise local summary, not full prescribing information.

Labeled basic dosing

For prophylaxis of invasive Aspergillus/Candida infections in severely immunocompromised adults: 300 mg orally twice on day 1, then 300 mg once daily from day 2. Duration follows recovery from neutropenia or immunosuppression. Swallow tablets whole.

RDM31-posaconazole-dr-label-dose · Source locator: 2.1, 2.2, 2.7, 2.9

Renal information and dialysis

The label keeps the same dosing in renal impairment. At eGFR below 20 mL/min/1.73 m2, monitor especially closely for breakthrough fungal infection because exposure is variable. Hemodialysis does not remove posaconazole.

RDM31-posaconazole-dr-label-renal · Source locator: 2.11; 8.6; 10

Selected warnings and limits

Do not substitute liquid formulations. Review CYP3A4 interactions, tacrolimus/cyclosporine exposure, QT/electrolyte risks and liver tests.

RDM31-posaconazole-dr-label-limits · Source locator: 4; 5; 7

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f795eca-7a03-4c91-9a0e-c1235791b665
Retrieved
2026-09-05
DailyMed Set ID
5f795eca-7a03-4c91-9a0e-c1235791b665
Renal-function method
eGFR mL/min/1.73 m2 for exposure-monitoring caution, not a reduced-dose algorithm.
Source date/version
Label revision date not separately recorded; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or label PDF.
Local summary SHA-256
de0cab71a35ce142136a6e1254e79afe328db282cbc8a10c5d9442e8968394f7
Separate professional-source layer

University and professional protocols

Professional

UCSF posaconazole - oral DR subset

Open original reference

Open / share this exact local source

University of California San Francisco (UCSF) · Adults receiving fungal prophylaxis with whole oral 100 mg delayed-release posaconazole tablets. The selected generic label is prophylaxis-only; oral suspension, PowderMix and IV formulations are excluded.

Renal method: Qualitative renal/HD guidance; CVVHD assumption from source
Source date: Revision date not stated on the reviewed page.
Retrieved: 2026-09-05

Separate professional-source protocol; not automatically equivalent to product labeling.

Source-specific renal protocol

For the delayed-release oral tablet portion of its protocol, UCSF uses 300 mg every 12 hours for two doses, then 300 mg every 24 hours without renal or HD dose reduction. It refers to therapeutic drug monitoring and warns that oral solution cannot be substituted. Intermittent HD assumes high-flux treatment; continuous guidance assumes CVVHD at 2 L/hour with residual native GFR.

RDM31-posaconazole-dr-prof-1 · Source locator: Adult/dialysis tables and Dialysis Notes; oral whole-DR-tablet subset

Source-specific limits

This local extraction excludes the page's IV and crushed-tablet regimens. The institution uses a broader indication scope than the selected generic prophylaxis-only label.

Source identity and provenance
Source
https://idmp.ucsf.edu/content/posaconazole
Retrieved
2026-09-05
Renal-function method
Qualitative renal/HD guidance; CVVHD assumption from source
Source date/version
Revision date not stated on the reviewed page.
Hash meaning
SHA-256 identifies the local paraphrase, not original source bytes.
Local summary SHA-256
b8eff91f6e869efe49e5470b62d296086a197941c184de0aae0ef332d21ea4e4

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f795eca-7a03-4c91-9a0e-c1235791b665
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
2ff0501e0ed27b2268719795dbcfc384cb59b13972e505eda5839bfd4e4ffaf0
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report